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Abstract
Objectives. Clinical practice guidelines based on the results of randomized clinical trials recommend that patients with heart
failure due to left ventricular systolic dysfunction (LVSD) be treated with angiotensin-converting enzyme inhibitors (ACEI) at
doses shown to reduce mortality and readmission. This study examined the relationship between ACEI use at discharge and
readmission among patients with heart failure due to LVSD.
Methods and results. Data were abstracted from the medical records of 2943 randomly selected patients hospitalized for heart
failure in 50 hospitals. The outcome of interest was the number of readmissions occurring up to 21 months after discharge. Six-
hundred and eleven patients were eligible for analysis. Compared with patients discharged at a recommended ACEI dose,
patients not prescribed an ACEI at discharge had an adjusted rate ratio of readmission (RR) of 1.74 [95% conWdence interval
(CI) 1.22–2.48], while patients prescribed an ACEI at less than a recommended dose had an RR of 1.24 (95% CI 0.91–1.69)
(P = 0.005 for the trend).
Conclusion. Our results show that ACEI use at discharge in patients with LVSD is associated with decreased rate of readmission.
These Wndings suggest that compliance with the ACEI prescribing recommendations listed in clinical practice guidelines for
patients with heart failure due to LVSD confers beneWt.
Keywords: angiotensin-converting enzyme inhibitors, heart failure, left ventricular systolic dysfunction, outcome assessment,
quality of health care, readmissions
Heart failure accounted for >605 000 (6.5%) of the ∼9.4
million total hospital discharges among Medicare beneWciaries
aged ≥65 years in 1995 [1]. The readmission rates within 2 and
30 days of discharge with heart failure as the primary diagnosis
were 21.4 per 1000 and 208.4 per 1000, respectively [1]. Heart
failure clearly imposes an extensive disease burden upon this
population.
Clinical practice guidelines recommend that patients with
heart failure due to left ventricular systolic dysfunction
(LVSD) be treated with angiotensin-converting enzyme
inhibitors (ACEIs) at doses shown to reduce mortality in ran-
domized clinical trials [2–5]. An overview of 30 randomized
clinical trials indicated that treatment with ACEI is effective
in reducing the risk of mortality and hospitalization (a com-
bined endpoint) for heart failure [6]. However, studies have
demonstrated that clinicians often fail to prescribe ACEI and
that a large percentage of their patients are not prescribed
ACEI at the proper dose [7–12]. We and others have shown
that failure to adhere to guidelines for ACEI prescription is
associated with higher mortality among patients with heart
failure due to LVSD in community hospitals [13,14]. The
purpose of this study was to examine the relationship
between ACEI use at discharge and hospital readmission
rates among Medicare patients treated in community hospitals
for heart failure due to LVSD. We also aimed to explore
whether results from randomized controlled trials can be
generalized to community hospitals.
Methods
Study design
This was a retrospective cohort study of Medicare patients who
were hospitalized for heart failure due to LVSD between 30
June 1995 and 30 September 1996. Follow-up for each patient
began on the date of discharge of the index hospitalization and
continued for 21 months.
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Study population
The study population was randomly selected from 50 com-
munity hospitals in Wve US states (Colorado, Connecticut,
Georgia, Oklahoma, and Virginia). Thirty-two hospitals out
of 50 participated voluntarily in a quality improvement trial.
Fifty participants within each hospital were randomly selected
Medicare beneWciaries with a primary diagnosis of heart
failure [International ClassiWcation of Diseases, 9th Revision,
Clinical ModiWcation (ICD-9-CM) codes 428 inclusive]. One
state used Diagnostic Related Group (DRG) code 127 (heart
failure) to identify eligible patients. If <50 eligible patients had
been discharged during the enrolment period, we evaluated all
admissions for heart failure. Patients were excluded from the
sample if the initial hospitalization was terminated against
medical advice, if they had been transferred to another hospital
(i.e. we would not obtain complete information about the
hospital stay and discharge), or if they died during the index
hospitalization. Additional exclusion criteria included age <65
years (Medicare population), contraindication to ACEI treat-
ment noted in the hospital chart, incomplete charts, secondary
causes for heart failure (aortic stenosis, mitral stenosis, acute
myocardial infarction, cor pulmonale, chronic obstructive
pulmonary disease treated with oxygen, thiamine deWciency,
amyloidosis, thyrotoxicosis), heart failure with preserved systolic
function, or no documentation regarding ventricular function.
Data
The data were abstracted from copies of hospital charts by
trained nurses and/or medical record specialists. Information
on patient and hospital characteristics, clinical and laboratory
results, and history and physical Wndings were abstracted
from the medical charts of the index hospitalization. Initial
and subsequent admissions were identiWed using the Health
Care Financing Administration MEDPRO Wle.
LVSD was deWned as any measured ejection fraction ≤40%
documented in the chart from a previous or the current hospi-
talization. If no information regarding ejection fraction was
found in the chart, patients were classiWed as having LVSD if
the narrative description of left ventricular function included
systolic dysfunction, dilated cardiomyopathy, cardiomyopathy,
and diffuse or global hypokinesis or ejection fraction (includ-
ing mildly, moderately, or severely reduced).
ACEIs identiWed in the hospital charts by generic or trade
name included benazepril, captopril, enalapril, fosinopril,
lisinopril, quinapril, and ramipril. Three treatment groups
were deWned based on ACEI prescription levels: target dose,
less than target dose, or no prescription at time of discharge.
Target levels were deWned as the dose found to reduce risk
of death in patients with LVSD in controlled clinical trials
(captopril 50 mg tid, enalapril 10 mg bid, lisinopril 20 mg qd,
ramipril 5 mg bid) [15]. If clinical trial evidence was unavailable,
target dose levels were based on the manufacturer’s stated
average doses (benazepril 20 mg qd, fosinopril 40 mg qd, and
quinapril 10 mg bid) [16].
A Deyo modiWcation of the Charlson comorbidity index
was used to compute a severity of illness index for each
patient [17]. The Charlson index is a weighted sum of selected
comorbidities. Discharge conditions from the index hospitali-
zation of each patient were used to compute the severity of
illness.
Statistical analysis
The dependent variable (outcome) was the number of
readmissions measured during seven distinct time periods
(0–3 months, >3–6 months, >6–9 months, >9–12 months,
>12–15 months, >15–18 months, and >18–21 months after
discharge from the index hospitalization). The primary expos-
ure variable was treatment group at time of index hospital
discharge (ACEI at target dose [reference], ACEI at suboptimal
dose, and no treatment with ACEI). Other variables included
in the analysis as potential confounders were age, sex, race,
the Charlson comorbidity index, and a history of heart failure,
diabetes mellitus, hypertension, prior myocardial infarction,
chronic obstructive pulmonary disease (COPD)/bronchitis,
or smoking. Additional covariates included Wndings of
paroxysmal nocturnal dyspnea (PND), dyspnea on exertion
(DOE), orthopnea, leg edema, pulmonary rales, jugular
venous dilatation (JVD), S3 gallop, ECG Wndings for atrial
Wbrillation, serum creatinine and potassium results, minimum
ejection fraction, length of stay, and hospital.
Intention to treat analysis was employed for the primary
exposure variable. For all time intervals, all patients were
analyzed as belonging to the ACEI treatment group at time of
index hospital discharge.
Patient characteristics at the index admission were tabulated.
Bivariate analyses were employed to describe the relationship
between patient characteristics and number of readmissions
in each treatment group. In all bivariate analyses, the crude
rates of readmission were calculated by dividing the number
of readmissions by the total living person-time in days for
each treatment group. Crude rate ratios were then estimated
and chi-square values were used to test for signiWcance. Life-test
procedures and survival analysis using a Cox model were used
to obtain Kaplan-Meier curves and to explore the relationship
between the time to Wrst readmission in each ACEI treatment
group, respectively. The proportional hazard assumption was
met in the Cox model [18].
A simple Poisson regression was used to calculate adjusted
rate ratios for the Wrst 3 months. Furthermore, a multivariate
correlated data analysis using Poisson regression and general-
ized estimating equations(GEE) considering Wxed effects was
performed [19–21]. This method accounts for the potential
correlation of repeated admissions for the same patient.
Because patients drawn randomly from the same hospital may
be more similar to one another in terms of exposure and out-
come status, we nested the patients within the index hospital.
In all analyses we used the date of death for censoring
patients who died during the follow-up period, and P < 0.05
as a cut-off value for signiWcance. We assessed interaction,
confounding, and model Wt [22]. A hierarchically well formu-
lated (HWF) model was formed with all covariates (previ-
ously described) entered into the model, as well as potential
interaction terms involving treatment group and the other
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covariates. Deviance values were used to assess the model Wt
[23]. Analyses were implemented with the SAS software (SAS
Institute Inc., Cary, NC, USA).
Results
There were 2943 eligible patients with a principal diagnosis of
heart failure at discharge from the participating hospitals
identiWed between 30 June 1995 and 30 September 1996. We
excluded 2332 (79.2%) of these patients from the analysis for
the following reasons: 267 (11.4%) were ineligible after initial
chart review because of an incomplete chart; 599 (25.7%) had
secondary causes for heart failure; 584 (25.0%) did not have
documented ventricular function; and 659 (28.3%) had left
ventricular diastolic dysfunction. Further, we excluded from
the analysis all patients who were aged <65 years, who died
during hospitalization, who were transferred to another
hospital, who had an incomplete chart, and who had a stated
contraindication to ACEI noted in the chart [a total of
223 (9.6%)].
Patient characteristics
There were 611 patients with LVSD remaining for analysis.
At discharge 128 (21%) were not prescribed ACE inhibitors,
367 (60%) were prescribed ACEI at levels less than target
dose, and 116 (19%) were prescribed target dose of ACEI.
The determination of LVSD was documented by a previous
or current ejection fraction for 509 (83%) patients and
depended on a narrative summary for 102 (17%) patients.
The mean age of patients was 77.5 (standard deviation 7.0)
years; 43% were female and 81% were white. A history of
previous heart failure was noted for 77%, a prior myocardial
infarction for 50%, COPD or bronchitis for 36%, hyperten-
sion for 67%, and diabetes for 41% of patients. Eleven per-
cent were current smokers. At admission, patients had the
following symptoms and Wndings: 36% PND, 40% DOE,
42% orthopnea, 67% leg edema, 85% pulmonary rales, 30%
S3 gallop, 50% JVD, and 25% atrial Wbrillation. The mean
minimum value of the current or previous ejection fraction
was 26%. The median Charlson comorbidity index was 2.
The median serum potassium and creatinine values were
4.2 mmol/l and 1.2 mg/dl, respectively. The median length of
stay was 5 days. A total of 256 (42%) patients died during the
follow-up period. Patient characteristics by ACEI group have
already been published in this journal [13].
Hospital readmissions
During the 21-month follow-up period, 425 (70%) patients
had at least one readmission. The number of readmissions per
patient varied from none to 18 (with a median of one). The
associations between patient characteristics and hospital
readmission rates by ACEI group (target dose ACEI, less
than target, and ACEI not prescribed) are shown in Tables 1
and 2. Patients not prescribed ACEI at discharge with prior
myocardial infarction and hypertension had signiWcantly
higher rates of readmission (Table 1). Opposite patterns were
observed for patients with history of heart failure, diabetes,
and who currently smoked. A statistically signiWcant increase
in admission rates was also observed with increases in both
the Charlson comorbidity index and in serum creatinine levels
for patients not prescribed ACEI (Table 2).
Association between ACEI use and readmission
First readmission. Among the patients with LVSD who
were prescribed ACEI at target dose, 71 (61%) had a Wrst
readmission; among those who were prescribed ACEI at
lower than target dose, 258 (70%) had a Wrst readmission;
and among those patients who did not receive ACEI at
discharge, 96 (75%) had a Wrst readmission (P = 0.041 for
the overall association; P = 0.021 between ‘at target dose
ACEI’ and ‘less than target’; and P = 0.310 between ‘less than
target’ and ‘no ACEI’). Patients treated according to clinical
guidelines had a longer time to Wrst readmission. The
median time before being readmitted was 258 days for patients
who were prescribed ACEI at target dose, 212 for patients
prescribed less than target dose, and 138 days for
patients who did not receive ACEI at discharge. Figure 1
shows the Kaplan-Meier survival curve to Wrst readmission
by level of ACEI dose. The log-rank test was statistically
signiWcant (P = 0.009). The adjusted hazard ratio [95%
conWdence interval (CI)] for the time to the Wrst readmis-
sion was 1.25 (0.95–1.64) for lower than target dose ACEI,
and 1.86 (1.34–2.60) when ACEI was not prescribed (target
dose = reference).
Frequency of readmission. Table 3 shows the rate ratios for
the 3-month time period and for the entire follow-up
period. There were 1119 readmissions (mean 1.8 per
patient) for the entire 21-month follow up period. The mean
number of readmissions per patient was 1.53 (177/116) for
patients who were prescribed target doses of ACEI at the
index discharge. The mean was 1.83 (673/367) for patients
prescribed ACEI at lower than target dose, and 2.10 (269/128)
for patients who were not prescribed ACE inhibitors.
Patients not prescribed ACEI at discharge had a 70%
increase in readmission rates [(RR) 1.70; 95% CI 1.40–2.07],
and patients at less than target dose a 31% increase (RR
1.31; 95% CI 1.11–1.56) compared with patients prescribed
the drug at target doses.
The Cox model presented under Wrst readmission takes
into account only the Wrst readmission and ignores that many
of the patients experienced multiple readmissions. We
therefore performed a second analysis. Using Poisson regression
and GEE procedures, we were able to incorporate the
frequency of readmission for each patient and to account for
the potential correlation of the data. In the Poisson multivariate
analysis, the adjusted rate ratio (95% CI) for the Wrst 3-month
period was 1.31 (0.92–1.87) for lower than target dose
ACEI, and 1.69 (1.13–2.54) when ACEI was not prescribed
(target dose = reference). Factors signiWcantly associated with
readmission during the Wrst 3 months included sex, history of
heart failure, hypertension, and length of stay. Finally, when
we accounted for the potential correlation of the data using
J.-C
. Luthi et al.
416 Table 1 Demographic characteristics, and symptoms and Wndings at admission of patients with left ventricular systolic dysfunction in relation to readmissions by level of
ACEI treatment (n = 611)
Patients’ characteristics
................................................................................................................................................................................................................................................
Crude rate ratio and 95% conWdence interval for readmissions ACEI dosage
n Target dose Less than target Not prescribed
............................................................................................................................................................................................................................................................................................................
Age quartiles
Q1: 64.5–72.1 years 152 Ref. Ref. Ref.
Q2: 72.1–77.2 years 153 0.84 (0.56–1.25) 1.13 (0.91–1.41) 1.07 (0.77–1.50)
Q3: 77.2–82.5 years 153 0.61 (0.38–0.97) 0.96 (0.77–1.21) 0.87 (0.61–1.26)
Q4: >82.5 years 153 0.78 (0.51–1.18) 1.25 (0.99–1.56) 0.79 (0.54–1.15)
Sex
Female 264 Ref. Ref. Ref.
Male 347 0.92 (0.67–1.24) 0.84 (0.72–0.97) 1.14 (0.89–1.46)
Race
Non-white 116 Ref. Ref. Ref.
White 493 0.78 (0.55–1.11) 1.02 (0.85–1.24) 1.21 (0.85–1.75)
History of heart failure
No 142 Ref. Ref. Ref.
Yes 469 2.43 (1.57–3.90) 1.84 (1.51–2.26) 1.75 (1.27–2.45)
Prior myocardial infarction
No 303 Ref. Ref. Ref.
Yes 308 1.27 (0.93–1.71) 1.06 (0.91–1.24) 1.33 (1.04–1.71)
COPD, bronchitis
No 390 Ref. Ref. Ref.
Yes 221 0.92 (0.65–1.28) 0.99 (0.84–1.16) 0.94 (0.71–1.22)
Hypertension
No 200 Ref. Ref. Ref.
Yes 411 0.94 (0.66–1.37) 1.11 (0.94–1.31) 1.42 (1.09–1.86)
Diabetes
No 363 Ref. Ref. Ref.
Yes 248 1.88 (1.38–2.56) 1.22 (1.04–1.42) 1.62 (1.27–2.07)
Current smoker
No 544 Ref. Ref. Ref.
Yes 67 0.76 (0.46–1.21) 0.81 (0.62–1.04) 0.52 (0.29–0.88)
Symptoms and Wndings
Paroxystal nocturnal dyspnea
No 394 Ref. Ref. Ref.
Yes 217 1.18 (0.87–1.60) 0.87 (0.74–1.02) 0.81 (0.60–1.08)
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ACEI, angiotensin-converting enzyme inhibitor; COPD, chronic obstructive pulmonary disease.
Table 1 continued
Patients’ characteristics
................................................................................................................................................................................................................................................
Crude rate ratio and 95% conWdence interval for readmissions ACEI dosage
n Target dose Less than target Not prescribed
............................................................................................................................................................................................................................................................................................................
Dyspnea on exertion
No 365 Ref. Ref. Ref.
yes 246 1.20 (0.88–1.64) 0.80 (0.68–0.93) 0.91 (0.70–1.17)
Orthopnea
No 356 Ref. Ref. Ref.
Yes 255 0.93 (0.68–1.26) 0.76 (0.65–0.89) 1.09 (0.85–1.40)
Leg edema
No 204 Ref. Ref. Ref.
Yes 407 1.07 (0.76–1.52) 1.06 (0.90–1.24) 1.24 (0.95–1.65)
Pulmonary rales
No 90 Ref. Ref. Ref.
Yes 521 0.64 (0.42–1.02) 0.79 (0.65–0.97) 0.95 (0.68–1.34)
S3 gallop
No 425 Ref. Ref. Ref.
Yes 186 1.01 (0.74–1.36) 1.18 (1.00–1.38) 1.08 (0.81–1.42)
Jugular vein distension
No 308 Ref. Ref. Ref.
Yes 303 1.11 (0.82–1.52) 1.36 (1.17–1.59) 1.18 (0.93–1.51)
Atrial Wbrillation
No 442 Ref. Ref. Ref.
Yes 145 0.92 (0.61–1.36) 0.94 (0.77–1.15) 0.98 (0.75–1.28)
J.-C. Luthi et al.
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GEE procedures, the adjusted RR for the entire 21-month
follow-up period was 1.24 (95% CI 0.91–1.69) for less than
target dose ACEI, and 1.74 (1.22–2.48) when ACEI was not
prescribed (Table 4). The trend (treatment effect) was statis-
tically signiWcant (P = 0.005). Other factors signiWcantly
associated with readmission in these correlated data analyses
included history of heart failure, diabetes, and elevated
creatinine level. Using the deviance as a statistical tool, our
Wnal model demonstrated a good Wt to the data (deviance/
degrees of freedom = 1.0326). Table 5 provides comparative
results between readmissions and our previous analysis on
mortality [13].
Discussion
Although several evidence-based guidelines recommend
ACEI prescription for patients such as those described
above, our study showed substantial variation in treatment.
For example, at discharge, 21% of the patients were not pre-
scribed ACEI and only 19% were prescribed ACEI at target
dose. This result is consistent with other studies that show a
large proportion of patients are not prescribed ACEI when
indicated or are prescribed ACEI at improper doses [7–12].
These results are particularly important in view of the sub-
stantial difference in the quality of medical care provided for
Medicare patients [24]. In particular, in a previous study we
found that failure to adhere to guidelines for ACEI prescrip-
tion was related to higher mortality among heart failure
patients [13]. Our study extends these Wndings to show
increased morbidity and rehospitalization in heart failure
patients where ACEI prescription fails to adhere to clinical
guidelines.
In our study, 70% of patients were readmitted at least once
within 21 months. This result is higher than reported in other
studies. In particular, a study in Connecticut with a similar
Table 2 Admission characteristics of patients with left ventricular systolic dysfunction in relation to readmissions by level of
ACEI treatment, n = 611
ACEI, angiotensin-converting enzyme inhibitor.
Patients’ characteristics
......................................................................................................................................................
Crude rate ratio and 95% conWdence interval for readmissions ACEI dosage
n Target dose Less than target Not prescribed
................................................................................................................................ .........................................................................................
Minimum ejection fraction
≤20% 162 1.28 (0.84–1.97) 1.27 (1.01–1.60) 1.33 (0.96–1.87)
21–30% 196 1.11 (0.74–1.69) 1.36 (1.09–1.71) 0.75 (0.54–1.04)
31–40% 151 Ref. Ref. Ref.
Charlson comorbidity index
1 187 Ref. Ref. Ref.
2 260 1.26 (0.88–1.84) 1.07 (0.89–1.29) 1.65 (1.17–2.35)
≤3 164 1.19 (0.74–1.90) 1.28 (1.05–1.57) 2.23 (1.57–3.22)
Potassium (mmol/l)
≤4.0 255 Ref. Ref. Ref.
4.1–5.0 323 1.03 (0.76–1.41) 0.85 (0.72–0.99) 0.98 (0.76–1.27)
>5.0 28 1.54 (0.48–3.74) 0.92 (0.60–1.34) 0.85 (0.41–1.58)
Creatinine (mg%)
≤1.0 189 Ref. Ref. Ref.
1.1–2.0 349 1.35 (0.96–1.93) 1.10 (0.93–1.31) 1.57 (1.16–2.16)
>2.0 68 1.37 (0.79–2.31) 1.40 (1.06–1.84) 2.10 (1.30–3.32)
Length of stay
1–5 days 349 Ref. Ref. Ref.
≥6 days 262 1.39 (1.00–1.90) 1.26 (1.08–1.47) 0.89 (0.69–1.13)
Table 3 Readmissions at 3, 6, 12, and 21 months after
discharge in patients with left ventricular systolic dysfunction
by level of ACEI treatment: bivariate analysis, n = 611
ACEI, angiotensin-converting enzyme inhibitor.
Crude rate ratio and 95% conWdence interval 
..................................................................................
for readmissions ACEI dosage
Target 
dose 
(n = 116)
Less than 
target 
(n = 367)
Not prescribed 
(n = 128)
..........................................................................................................
Readmissions at
3 months 1.00 (Ref.) 1.27 (0.93–1.77) 1.47 (1.02–2.15)
6 months 1.00 (Ref.) 1.18 (0.92–1.52) 1.49 (1.12–1.99)
12 months 1.00 (Ref.) 1.18 (0.98–1.44) 1.52 (1.22–1.91)
21 months 1.00 (Ref.) 1.31 (1.11–1.56) 1.70 (1.40–2.07)
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population of Medicare beneWciaries found that 44% were
readmitted at 18 months [25]. In our study, 62% of patients
had had at least one readmission at 18 months. We also found
the same result for patients from Connecticut only. However,
in the latter study all patients with heart failure were included;
in our study only patients with LVSD were included. In
another study, the 90-day risk of a Wrst readmission varied
between 29% and 42% [26].
Our study results show that patients with LVSD who
receive no ACEI or who receive less than target doses of
ACEI have a higher rate of readmission than those who
receive target ACEI doses. These results are consistent with
those from a multi-centered randomized controlled trial per-
formed with 3164 patients with New York Heart Association
II to IV heart failure and an ejection fraction ≤30% [27].
Patients were assigned either a low-dose (2.5–5.0 mg daily) or
high-dose (32.5–35 mg daily) regimen of the ACE inhibitor
lisinopril (ATLAS study). The authors observed a 13%
decrease in the risk of hospitalization for any cause, and a
24% decrease of hospitalization for heart failure between the
low- and the high-dose group. They concluded that target
doses of ACEI should be prescribed to patients with heart
failure due to LVSD to reduce readmissions [27]. Other studies
have also demonstrated measurable effects on readmission
for patients treated with ACE inhibitors [28,29]. A recent
meta-analysis of Wve randomized, placebo-controlled trials of
ACEI use in patients with heart failure or left ventricular
dysfunction (n = 12 763) convincingly showed that treatment
with ACEI reduces the risk of death: [odds ratio (OR) 0.80;
95% CI 0.74–0.87] [30]. Furthermore, the same study showed
that the risk of readmission for heart failure was also reduced
by treatment with ACEI (OR 0.67; 95% CI 0.61–0.74).
Therefore, prescription of ACEI for patients who suffer from
heart failure due to LVSD could be considered an indicator of
quality of care.
Our study has some limitations. Firstly, current national
guidelines for heart failure treatment recommend the use of
ACEI at target dose. However, individual patient factors may
preclude following recommended guidelines. While we con-
trolled for some of these factors (e.g. creatinine), we cannot
exclude the possibility that other patient characteristics
account for failure to treat according to guidelines. Secondly,
we have assumed that all patients remained on the same
treatment type and dose as prescribed at index discharge, and
Table 4 Readmissions in relation to ACEI dose for patients with left ventricular systolic dysfunction: multivariate analysis
using Poisson regression and GEE procedures, n = 611
ACEI, angiotensin-converting enzyme inhibitor; CI, conWdence interval; GEE, generalized estimating equations.
Parameter 
estimate
Standard 
error
P value Adjusted 
rate ratio
Lower 
95% CI
Upper 
95% CI
................................................................................................................................ .........................................................................................
Intercept −6.738 0.334 <0.001
Target Ref. Ref. Ref. 1.00 Ref. Ref.
Less than target 0.214 0.158 0.173 1.24 0.91 1.69
ACEI not prescribed 0.555 0.181 0.002 1.74 1.22 2.48
Sex 0.178 0.114 0.117 1.20 0.96 1.49
History of heart failure 0.593 0.126 <0.001 1.81 1.41 2.32
Diabetes 0.344 0.113 0.002 1.41 1.13 1.76
Minimum ejection fraction −0.009 0.006 0.137 0.99 0.98 1.00
Creatinine 0.185 0.075 0.013 1.20 1.04 1.39
Length of stay (continuous) 0.012 0.011 0.110 1.02 1.00 1.04
Table 5 Mortality and readmissions of patients with left ventricular systolic dysfunction by level of ACEI treatment, n = 621
ACEI, angiotensin-converting enzyme inhibitor; CI, conWdence interval.
.......................................................................................
Mortality (12 months) [13], n = 621
.......................................................................................
Readmissions (21 months), n = 611
Crude risk 
(95% CI)
Adjusted hazard ratio 
(95% CI)
Crude rate ratio 
(95% CI)
Adjusted rate ratio 
(95% CI)
................................................................................................................................ ..........................................................................................
ACEI dose
Target 1.00 1.00 1.00 1.00
Less than target 1.36 (0.95–1.92) 1.30 (0.86–1.97) 1.31 (1.11–1.56) 1.24 (0.91–1.69)
Not prescribed 1.69 (1.16–2.47) 1.63 (1.02–2.60) 1.70 (1.40–2.07) 1.74 (1.22–2.48)
J.-C. Luthi et al.
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that there was patient compliance. This assumption fails to
account for a necessary period of dose titration to target levels
(approximately 2–3 weeks). Therefore, we could have
misclassiWed patients who actually received target levels of
ACEI. Thirdly, the outcome of interest (number of readmis-
sions) was collected from the medical record of each patient
without taking into account the reason for readmission (ICD-9
codes were not available). Some of the readmissions could be
unrelated to the disease of interest (e.g. trauma). A potential
for overestimation of readmission rates in each treatment
group is therefore created. Furthermore, if the readmissions
not related to heart failure disease differ among treatment
groups, a potential for bias is created. Fourthly, although we
excluded patients with contraindications to ACEI documented
in the chart (particularly hypotension), we did not have a
measure of discharge systolic blood pressure. Some patients
with severe heart failure and low blood pressure may have
contraindication to ACEI, therefore are more prone to
readmission. This is a factor that may have inXuenced our
results and that we were not able to control for. Fifthly, it is
possible that some heart failure readmissions that occurred in
Veterans Affairs (VA) hospitals were missed [31]. Sixthly, it is
possible that some patients hospitalized for symptoms due to
heart failure, but labeled as some other condition at discharge,
were not included in our analysis, which might have introduced
a selection bias. Finally, hospital participation is on a voluntary
basis. This may create a potential selection bias and limits the
generalization of our results.
In conclusion, we observed a variation in treatment and in
treatment effect. We found a steadily decreasing rate of
readmission among patients treated with a target dose of
ACEI compared with those receiving subtarget, and with
those with no prescription for ACEIs. The trend of treatment
effect was statistically signiWcant even after adjusting for
known and potential confounding factors. These results were
observed during the Wrst 3 months and after prolonged
follow-up. The variation in ACEI use in our study shows a
treatment effect in the Wrst 3 months consistent with
guideline recommendations. Furthermore, our results indicate
that variations in ACEI prescription identify groups who will
have different outcomes over prolonged follow-up, even after
accounting for severity of illness. Our Wndings suggest that
compliance with ACEI prescribing guidelines confers beneWt
to patients with heart failure due to LVSD in community hospi-
tals. Clinicians should consider following the recommended
guidelines when managing these patients.
Acknowledgements
The analyses upon which this publication is based were
performed under the following contracts: (1) 500-96-704,
entitled Utilization and Quality Control Peer Review Organization
for the State of Georgia; (2) 500-99-P619, entitled Utilization and
Quality Control Peer Review Organization for the State of
Oklahoma; (3) 500-96-P538, entitled Utilization and Quality
Control Peer Review Organization for the Commonwealth of
Virginia; (4) 500-96-P549, entitled Utilization and Quality
Control Peer Review Organization for the State of Connecticut; and
(5) 500-96-P611, entitled Utilization and Quality Control Peer
Review Organization for the State of Colorado, which were each
sponsored by the Health Care Financing Administration,
Department of Health and Human Services. The content of
this publication does not necessarily reXect the views or
policies of the Department of Health and Human Services,
nor does mention of trade names, commercial products, or
organizations imply endorsement by the US Government.
The authors assume full responsibility for the accuracy and
completeness of ideas presented. This article is a direct
result of the Health Care Quality Improvement Program
initiated by the Health Care Financing Administration,
which has encouraged identiWcation of quality improvement
projects derived from analysis of patterns of care, and therefore
required no special funding on the part of this contractor.
References
1. Dicker RC, Ordin DL, Han LF, Campbell MK. Introducing
the Medicare Quality of Care Surveillance System. Quality Résumé,
No. 1. Baltimore, MD: Health Care Financing Administration, 1997.
2. Williams JF, Bristow MR, Fowler MB et al. Guidelines for the
evaluation and management of heart failure: report of the
American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on Evaluation
and Management of Heart Failure). J Am Coll Cardiol 1995; 26:
1376–1398.
3. Konstam MA, Dracup K, Baker DW et al. Heart Failure: Evaluation
and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical
practice guideline No. 11. Rockville, MD: Agency for Health Care
Policy and Research, Public Health Service, US Department of
Health and Human Services, June 1994 (publication No. AHCPR
94-0612).
4. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for
the evaluation and management of chronic heart failure in the
adult: executive summary. A report of the American College of
Cardiology/American Heart Association Task Force on Prac-
tice Guidelines (Committee to Revise the 1995 Guidelines for
the Evaluation and Management of Heart Failure). Circulation
2001; 104: 2996–3007.
5. European Society of Cardiology, Task Force of the Working
Group on Heart Failure of the European Society of Cardiology.
Guidelines for the diagnosis of heart failure. Eur Heart J 1999; 16:
741–745.
6. Garg R, Yusuf S. Overview of randomized trials of angiotensin-
converting enzyme inhibitors on mortality and morbidity in
patients with heart failure. J Am Med Assoc 1995; 273: 1450–1456.
7. Philbin EF, Andreou C, Rocco TA Jr, Lynch LJ, Baker SL.
Patterns of angiotensin-converting enzyme inhibitor use in
heart failure in two community hospitals. Am J Cardiol 1996;
77: 832–838.
8. Croft JH, Giles WH, Roegner RH, Anda RF, Casper ML,
Livengood JR. Pharmacologic management of heart failure
among older adults by ofWce-based physicians in the United
States. J Fam Prac 1997; 44: 382–390.
Readmissions and the quality of care
421
9. Stafford RS, Saglam D, Blumenthal D. National patterns of
angiotensin-converting enzyme inhibitor use in heart failure.
Arch Intern Med 1997; 157: 2242–2247.
10. The Large State Peer Review Organization Consortium. Heart
failure treatment with angiotensin-converting enzyme inhibitors
in hospitalized Medicare patients in 10 large states. Arch Intern
Med 1997; 157: 1103–1108.
11. Krumholz HM, Wang Y, Parent EM et al. Quality of care for
elderly patients hospitalized with heart failure. Arch Intern Med
1997; 157: 2242–2247.
12. Luthi JC, McClellan WM, Fitzgerald D et al. Variations among
hospitals in the quality of care for Medicare beneWciaries with
heart failure. Eff Clin Pract 2000; 3: 69–77.
13. Luthi JC, McClellan WM, Fitzgerald D et al. Mortality associated
with the quality of care of patients hospitalized with heart
failure. Intern J Qual Health Care 2002; 14: 15–24.
14. Havraneck EP, Abbrams F, Stevens E, Parker K. Determinants
of mortality in elderly patients with heart failure. The role of
angiotensin-converting enzyme inhibitors. Arch Intern Med 1998;
158: 2024–2028.
15. Cleland JGF, Hubbard WN, Pittard J, Poole-Wilson PA,
Sutton GC. ACE inhibitors in heart failure: What dose? Br Med J
1995; 71: 65–66.
16. Physician Desk Reference (PDR), 50th ed. Montvale, NJ: Medical
Economics Publications, 1996.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbid-
ity index for use with ICD-9 CM administrative databases. J Clin
Epidemiol 1992; 45: 613–619.
18. Kleinbaum DG. Survival Analysis: A Self-Learning Text. New York:
Springer Verlag, 1996.
19. Zeger SL, Liang KY. Longitudinal data analysis for discrete and
continuous outcomes. Biometrics 1986; 42: 121–130.
20. Ware J. Linear models for the analysis of several measurements
in longitudinal studies. Am Statist 1985; 39: 95–101.
21. Kleinbaum DG, Kupper LL, Morgenstern H. Applied regres-
sion analysis and other multivariate methods. Belmont, CA:
Duxbury Press, 1988.
22. Kleinbaum DG. Logistic Regression: A Self-Learning Text. New
York: Springer Verlag, 1994.
23. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York:
Wiley Interscience, 1989.
24. Jencks SF, Cuerdon T, Burwen DR et al. Quality of medical care
delivered to Medicare beneWciaries. A proWle at state and
national levels. J Am Med Assoc 2000; 284: 1670–1676.
25. Krumholz HM, Parent EM, Tu N et al. Readmission after
hospitalization for heart failure among Medicare beneWciaries.
Arch Intern Med 1997; 157: 99–104.
26. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE,
Carney RM. A multidisciplinary intervention to prevent the
readmission of elderly patients with heart failure. N Engl J Med
1995; 333: 1190–1195.
27. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative
effects of low and high doses of the angiotensin-converting
enzyme inhibitor, Lisinopril, on morbidity and mortality in
chronic heart failure. Circulation 1999; 100: 2312–2318.
28. McDermott MM, Lee P, Mehta S, Gheorghiade M. Patterns of
angiotensin-converting enzyme inhibitor prescriptions, educa-
tional interventions, and outcomes among hospitalized patients
with heart failure. Clin Cardiol 1998; 21: 261–268.
29. Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL Jr.
Containment of heart failure hospitalizations and cost by
angiotensin-converting enzyme inhibitor dosage optimization.
Am J Cardiol 2000; 86: 519–523.
30. Flather MD, Yusuf S, Kober L et al. For the ACE-Inhibitor
Myocardial Infarction Collaborative Group. Long-term ACE-
inhibitor therapy in patients with heart failure or left ventricular
dysfunction: a systematic overview of data from individual
patients. Lancet 2000; 355: 1575–1581.
31. Fleming C, Fisher ES, Chang CH, Bubolz TA, Malenka DJ.
Studying outcomes and hospital utilization in the elderly. The
advantages of a merged data base for Medicare and Veterans
Affairs hospitals. Medical Care 1992; 30: 377–391.
Accepted for publication 9 April 2003

